Compare Recursion Pharmaceuticals Inc (RXRX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B), while Teradyne, Inc. trades at $402.42 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 29.1× Recursion Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Teradyne, Inc. for 37 Days on average.
| RXRX | TER | |
|---|---|---|
Market Cap | $2.14B | $62.34B |
Volume | 30,789,535 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $6.79 | $483.84 |
52-Week Low | $2.84 | $132.05 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $1.66B | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Teradyne (TER) trades at $403.88, down 1.92% on the day, yet maintains a bullish technical stance with strong analyst support. The company exhibits robust profitability with a 25.77% net income margin and 36.66% ROE, supported by consecutive earnings beats. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, positioning TER to capitalize on semiconductor and data center demand growth.
The outlook is positive, driven by strategic product launches and strong earnings momentum, with a consensus price target of $461.50 implying ~14% upside. Key risks include execution challenges in a competitive semiconductor equipment market and sensitivity to cyclical industry demand, which could pressure valuation multiples if growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
